Only 12% of people between the ages of 50 and 64 say they’re very likely to step forward to test a new dementia-prevention drug, and 32% say they’re somewhat likely, according to a new poll.

Researchers are working urgently to find and test new medications that could prevent or slow the decline of brain function in older adults. The new study suggests they’ll need to work harder to find volunteers for their clinical trials.

Those who have a family history of Alzheimer’s disease or another form of dementia, or who believe they’re likely to develop dementia, are more than twice as likely to say they’d sign up to test a new drug. So are those who have talked about dementia prevention with a doctor—but they accounted for only 5% of those surveyed.

The data for the study came from the National Poll on Healthy Aging, based at the University of Michigan Institute for Healthcare Policy and Innovation. Researchers from the University of Michigan School of Public Health did an in-depth analysis of the responses from a national sample of more than 1,000 adults in their 50s and early 60s.

“With Alzheimer’s disease and other forms of dementia affecting millions of older Americans and their families, and costing hundreds of billions of dollars in care, finding new options for preventing and slowing cognitive decline is a critical national goal,” says Scott Roberts, the poll’s associate director, professor at the School of Public Health, and leader of the Outreach, Recruitment & Engagement Core at the Michigan Alzheimer’s Disease Center.

“Our analysis shows that the 56% of respondents who say they’re not likely to take part in a dementia prevention drug trial mainly cite concerns over being a ‘guinea pig’ or the potential for harm, but nearly 1 in 4 said it’s because they don’t think dementia will affect them,” says first author Chelsea Cox, a doctoral student in public health.

“However, as other research has shown, one-third of people over 65 have dementia or mild cognitive impairment, and the rate rises steadily with age.”

The researchers note that current drug trials for dementia prevention often fail to recruit a nationally representative pool of participants. This means that the results of such studies used to seek approval to market new treatments may not accurately represent the drugs’ performance across different racial and ethnic groups.

Read the full article about dementia drugs by Kara Gavin at Futurity.